Physicians Financial Services Inc. Has $5.65 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Physicians Financial Services Inc. lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,547 shares of the medical research company’s stock after selling 565 shares during the period. Amgen comprises 1.8% of Physicians Financial Services Inc.’s portfolio, making the stock its 13th biggest holding. Physicians Financial Services Inc.’s holdings in Amgen were worth $5,654,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Meyer Handelman Co. grew its stake in shares of Amgen by 7.2% in the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock valued at $40,566,000 after purchasing an additional 8,700 shares during the period. EP Wealth Advisors LLC increased its position in shares of Amgen by 11.0% during the 1st quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock worth $6,758,000 after purchasing an additional 2,353 shares in the last quarter. Stanley Laman Group Ltd. bought a new stake in Amgen during the second quarter worth about $3,354,000. Verity & Verity LLC raised its stake in shares of Amgen by 2.7% in the second quarter. Verity & Verity LLC now owns 82,368 shares of the medical research company’s stock valued at $25,736,000 after acquiring an additional 2,182 shares during the last quarter. Finally, Matrix Asset Advisors Inc. NY boosted its holdings in shares of Amgen by 9.3% in the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 45,068 shares of the medical research company’s stock worth $14,081,000 after acquiring an additional 3,845 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.7 %

AMGN traded up $2.13 during trading on Friday, reaching $324.04. 119,055 shares of the company’s stock were exchanged, compared to its average volume of 2,401,752. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a one year low of $260.52 and a one year high of $346.85. The firm has a fifty day moving average price of $323.96 and a two-hundred day moving average price of $316.68. The stock has a market capitalization of $174.18 billion, a PE ratio of 41.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the business posted $4.96 earnings per share. As a group, equities research analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and set a $362.00 price target on shares of Amgen in a research note on Thursday, September 26th. TD Cowen upped their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. UBS Group cut their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $333.50.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.